News articles about Mallinckrodt (NYSE:MNK) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mallinckrodt earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.8695347746407 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Reality Catches Up To Mallinckrodt 4 Years Later – Seeking Alpha (seekingalpha.com)
- Reality Catches Up To Mallinckrodt 4 Years Later – Mallinckrodt PLC … – Seeking Alpha (seekingalpha.com)
- Mallinckrodt, Upcoming PDUFA Date, Analysts Review and Target, and Potential Catalysts (finance.yahoo.com)
- Mallinckrodt Completes Sale Of RECOTHROM® And PREVELEAK® To Baxter (bizjournals.com)
- Mallinckrodt plc (MNK) Estimates, PT Lowered to $17.50 at Wells Fargo – StreetInsider.com (streetinsider.com)
A number of analysts have recently commented on the company. Oppenheimer reissued a “hold” rating on shares of Mallinckrodt in a research note on Tuesday, February 27th. Wells Fargo set a $18.00 price target on Mallinckrodt and gave the company a “hold” rating in a research note on Friday, March 16th. Zacks Investment Research raised Mallinckrodt from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Goldman Sachs reissued a “hold” rating on shares of Mallinckrodt in a research note on Monday, January 1st. Finally, Canaccord Genuity set a $24.00 price target on Mallinckrodt and gave the company a “hold” rating in a research note on Tuesday, December 26th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $38.50.
Mallinckrodt (NYSE:MNK) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $2.01 EPS for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.29. The company had revenue of $792.30 million for the quarter, compared to analyst estimates of $769.91 million. Mallinckrodt had a return on equity of 13.43% and a net margin of 66.25%. The firm’s quarterly revenue was down 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.91 earnings per share. analysts predict that Mallinckrodt will post 6.2 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Mallinckrodt (MNK) Given Daily Media Sentiment Score of 0.23” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2018/03/21/mallinckrodt-mnk-given-daily-media-sentiment-score-of-0-23.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.